Skip to main content
. Author manuscript; available in PMC: 2023 Jun 2.
Published in final edited form as: Cell Stem Cell. 2022 May 3;29(6):905–917.e6. doi: 10.1016/j.stem.2022.04.006

Figure 4.

Figure 4.

Immune cells preserved in MOS are responsive to immunotherapy. (A) Nivolumab induced significant cytotoxicity in tumorspheres within MOS. Incucyte images were taken every 2 hours for 4 days, and Annexin V Green dye was added to indicate apoptosis. (B) Representative images from Incucyte demonstrated Nivolumab induces cell apoptosis within MOS. (C) Established MOS (day 4) derived from lung tumor tissue. (D) Animation of how ESK1* TCB drug induces CTL-mediated killing in MOS. (E) HLA-A2 gene expression in lung tumor tissues. (F) HLA-A2 expression detected by flow cytometry in established MOS derived from lung tumor tissue. (G) ESK1* induced higher apoptosis signal (indicated by Annexin V signal) in MOS. (H) Representative images of apoptosis induced by ESK1* treatment. (I) ESK1* induced killing of lung cancer MOS in all eight lung cases (p<0.005).